NCT03860857 · Phase 3 · RECRUITING

Biomarker Exploration in Aging, Cognition and Neurodegeneration

This observational study is tracking brain changes in people 60 and older who currently have normal cognition. Researchers are using MRI, amyloid PET, tau PET, and cognitive testing to see which early brain changes best predict future memory decline. There is no drug treatment involved — this is a measurement and monitoring study. Phase 3 here means the imaging and testing methods are being validated at a larger scale, not that a therapy is being tested.

You may qualify if

  • Aged 60 or older;
  • Speaks fluent English or Spanish;
  • Visual and auditory acuity adequate for neuropsychological and computerized testing;
  • Good general health with no disease(s) expected to interfere with the study;
  • Willing and able to participate for the duration of the study and in all study procedures including MRI and PET;
  • Normal cognition defined as a Clinical Dementia Rating of 0 and a Mini-Mental State Examination score of 25 or higher. FAST Stage 1 or 2.
  • Subjective memory or other cognitive complaints will be included.

You're excluded if

  • Significant co-morbid neurologic disease such as Parkinson's disease, multiple sclerosis, brain cyst, tumor or aneurysm;
  • Major health conditions, except for Type II diabetes mellitus, hypercholesterolemia, and hypertension, which are NOT exclusionary for this study given their high prevalence in our target populations;
  • Significant psychiatric disorders such as schizophrenia, bipolar disorder, or attention-deficit hyperactivity disorder, except for depression and anxiety, which are NOT exclusionary for this study given their high prevalence in our target populations;
  • Existing diagnosis of dementia or mild cognitive impairment;
  • Alcohol or substance abuse or dependence within the past 2 years (DSM-IV criteria);
  • MRI contraindications, e.g. pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body. Females who are pregnant or trying to get pregnant are also excluded;
  • PET contraindications, e.g. significant prior radiation exposure and pregnancy.

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2026-01-23

View full record on ClinicalTrials.gov

All APOE4 clinical trials